Allied Gold stock rebounds as gold prices bounce back after sharp selloff

Allied Gold stock rebounds as gold prices bounce back after sharp selloff

NEW YORK, December 30, 2025, 10:15 ET — Regular session

  • Allied Gold Corporation shares rose about 3% in morning trading after Monday’s slide.
  • Gold prices rebounded as traders unwound year-end profit-taking and repositioned.
  • Investors are watching the Federal Reserve’s December meeting minutes later Tuesday for rate clues.

Allied Gold Corporation shares were up 71 cents, or about 3.1%, at $23.67 in morning trading on Tuesday.

The move tracked a broader rebound in precious-metals-linked names after bullion swung sharply over the past two sessions.

That matters now because thin year-end liquidity can exaggerate moves, and gold’s price swings tend to ripple quickly into miners’ shares, which investors often treat as leveraged bets on the metal.

Gold fell hard on Monday after hitting a record high late last week, as traders locked in profits following the rally. Spot gold dropped 4.5% to $4,330.79 an ounce by 1:51 p.m. ET after touching a record $4,549.71 on Friday, Reuters reported. Reuters

On Tuesday, spot gold recovered, and the tone improved across the complex. “The selloff yesterday had the hallmarks of profit taking and repositioning ahead of the new year,” said Zain Vawda, an analyst at MarketPulse by OANDA, in a Reuters report that put spot gold up 1.6% and U.S. gold futures up 1.7%. Reuters

Allied Gold, which operates a portfolio of mines and development projects in West Africa and Ethiopia, tends to trade with swings in bullion because its revenue is tied to the gold price. Reuters

In Canada, the S&P/TSX composite index opened higher on Tuesday, helped by a rebound in mining shares as gold and silver prices stabilized after the prior day’s drop, Reuters reported. Reuters

Bigger peers also firmed as bullion rebounded. Newmont, the world’s largest listed gold miner, gained 0.8% in early trade, Barron’s reported. Barron’s

The wider U.S. tape was more cautious, with Wall Street opening subdued after a tech-led pullback in the prior session, Reuters reported. Reuters

Traders’ next focus is the Fed’s December meeting minutes due later Tuesday, after recent market pricing for rate cuts in 2026 helped fuel demand for gold, which pays no interest.

Stock Market Today

  • CorMedix (CRMD) Shares Fall 43% Yet Show Signs of Deep Undervaluation
    January 20, 2026, 6:53 AM EST. CorMedix (CRMD) has seen its share price drop by 43.6% in 30 days and nearly 45.7% over the past year despite a positive three-year return of 56.2%. The decline comes amid volatility tied to market sentiment and its pharmaceutical product pipeline prospects. A Discounted Cash Flow (DCF) analysis by Simply Wall St estimates an intrinsic value of $72.83 per share, implying the stock is roughly 90.7% undervalued compared to the recent price near $6.78. The DCF model forecasts CorMedix's free cash flow rising to $241.8 million by 2030. Investors should weigh CorMedix's current valuation against industry peers and growth risks. The stock's ongoing P/E ratio and pipeline developments remain key watch points for value assessment.
JPMorgan stock slips in early trade as Fed minutes and year-end funding signals take focus
Previous Story

JPMorgan stock slips in early trade as Fed minutes and year-end funding signals take focus

Why Caterpillar stock is slipping today: AI data-center power bets meet year-end trading
Next Story

Why Caterpillar stock is slipping today: AI data-center power bets meet year-end trading

Go toTop